In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...
Read More
In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (LT) for recurrent or non-responding non-Hodgkin’s lymphoma (NHL). This study found that LT showed promising effectiveness, with manageable side effects. Some background Patients with NHL often receive strong treatment to kill cancer cells. 60 to 70%...
Read More
In a nutshell This study examined the safety and effectiveness of combining brentuximab vedotin (Adcetris) and bendamustine (Treanda) in patients with reoccurring or unresponsive Hodgkin lymphoma (HL). The authors concluded that this regimen shows promise in HL which is difficult to treat. Some...
Read More
In a nutshell This article outlined recommended treatments for patients with Hodgkin's lymphoma (HL). Some background HL is a type of blood cancer of the lymphatic system. HL can be classified in different ways. In limited HL, cancer is found in one or two sites in the lymphatic system. In advanced HL, cancer is found on both sides of...
Read More
In a nutshell This study investigated whether older patients with Hodgkin lymphoma (HL) were at high risk for developing lung side effects when treated with bleomycin (Blenoxane). The authors found that the odds of developing lung side effects increased significantly with age in these patients. Some background For patients with HL, age is one of...
Read More
In a nutshell This study compared the effectiveness of brentuximab vedotin (Adcetris) to chemotherapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding after a stem cell transplant (SCT). This study concluded that patients treated with brentuximab vedotin had better outcomes compared to patients in the...
Read More
In a nutshell This study evaluated the quality of life reported by elderly patients with non-Hodgkin's lymphoma (NHL) after a stem cell transplant (SCT). The authors concluded that quality of life for these patients was very good following SCT. Some background Autologous SCT is the standard of care in first-line treatment for...
Read More
In a nutshell This study evaluated the outcomes of allogeneic stem cell transplantation (SCT) in patients with classical Hodgkin’s lymphoma (CHL) that was refractory (resistant to treatment) or had relapsed. The study found that patients in complete remission (no signs of cancer) when they received the transplant had better outcomes. Some...
Read MoreIn a nutshell This trial is examining the effectiveness of modified stem cell transplants (SCT) donated by patient relatives, which have certain immune cells removed to prevent transplant rejection in patients with leukemia and lymphoma. The main outcome will be the maximum dose of SCT that can be given safely and is effective. This study is recruiting...
Read More
In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read More
In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read More
In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...
Read More
